	US 12,005,063 B2
	Medicament for preventing and/or treating dry eye
Kenji Oki, Minoh (JP); Takashi Nagano, Osaka (JP); Nagayoshi Asano, Ikoma (JP); and Koushi Fujisawa, Ikoma (JP)
Assigned to SANTEN PHARMACEUTICAL CO., LTD., Osaka (JP); and BOEHRINGER INGELHEIM INTERNATIONAL GMBH, Ingelheim am Rhein (DE)
Filed by Santen Pharmaceutical Co., Ltd., Osaka (JP); and Boehringer Ingelheim International GMBH, Ingelheim am Rhein (DE)
Filed on Apr. 18, 2022, as Appl. No. 17/722,947.
Application 17/722,947 is a continuation of application No. 17/513,593, filed on Oct. 28, 2021, granted, now 11,331,322.
Claims priority of application No. 2021-150112 (JP), filed on Sep. 15, 2021.
Prior Publication US 2023/0087826 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 265/36 (2006.01); A61K 31/536 (2006.01); A61P 27/04 (2006.01)

CPC A61K 31/536 (2013.01) [A61P 27/04 (2018.01)]

11 Claims

1. A method of treating dry eye in a subject in need thereof, comprising administering a therapeutically effective amount of olodaterol hydrochloride to the subject.